You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 2 | BMC Infectious Diseases

Figure 2

From: High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

Figure 2

Cumulative incidence of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) among patients treated with interferon-alpha. Left side, cumulative incidence of LC among 163 baseline non-cirrhotic patients with sustained virological response (SVR, solid line) and without SVR (dotted line) to interferon-alpha therapy. P = 0.067 by the log-rank test. The number of LC events and patients at risk at each time point are shown below the graph. Right side, cumulative incidence of HCC among 200 patients with SVR (solid line) and without SVR (dotted line) to interferon-alpha therapy. P < 0.01 by the log-rank test. The number of HCC events and patients at risk at each time point are shown below the graph.

Back to article page